Notably, the S1PR1 signalling is recognised as a therapeutically actionable target, with small-molecule modulators of S1PR1 showing potential to disrupt tumour-promoting signalling networks and overcome drug resistance in various cancers [3,4,5]. This evidence concerns the gene S1PR1 and cancer.